AU2002320385B2 - Sequential drug delivery systems - Google Patents

Sequential drug delivery systems Download PDF

Info

Publication number
AU2002320385B2
AU2002320385B2 AU2002320385A AU2002320385A AU2002320385B2 AU 2002320385 B2 AU2002320385 B2 AU 2002320385B2 AU 2002320385 A AU2002320385 A AU 2002320385A AU 2002320385 A AU2002320385 A AU 2002320385A AU 2002320385 B2 AU2002320385 B2 AU 2002320385B2
Authority
AU
Australia
Prior art keywords
active ingredient
adjusting
substances
substance
localized environment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002320385A
Other languages
English (en)
Other versions
AU2002320385A1 (en
Inventor
John Hontz
S. Indiran Pather
John M. Siebert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cima Labs Inc
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of AU2002320385A1 publication Critical patent/AU2002320385A1/en
Application granted granted Critical
Publication of AU2002320385B2 publication Critical patent/AU2002320385B2/en
Priority to AU2008203464A priority Critical patent/AU2008203464B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002320385A 2001-07-10 2002-07-10 Sequential drug delivery systems Ceased AU2002320385B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008203464A AU2008203464B2 (en) 2001-07-10 2008-08-01 Sequential drug delivery systems

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/901,983 2001-07-10
US09/901,983 US20030068356A1 (en) 2001-07-10 2001-07-10 Sequential drug delivery systems
PCT/US2002/021796 WO2003005944A1 (en) 2001-07-10 2002-07-10 Sequential drug delivery systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008203464A Division AU2008203464B2 (en) 2001-07-10 2008-08-01 Sequential drug delivery systems

Publications (2)

Publication Number Publication Date
AU2002320385A1 AU2002320385A1 (en) 2003-05-22
AU2002320385B2 true AU2002320385B2 (en) 2008-05-01

Family

ID=25415151

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002320385A Ceased AU2002320385B2 (en) 2001-07-10 2002-07-10 Sequential drug delivery systems
AU2008203464A Ceased AU2008203464B2 (en) 2001-07-10 2008-08-01 Sequential drug delivery systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008203464A Ceased AU2008203464B2 (en) 2001-07-10 2008-08-01 Sequential drug delivery systems

Country Status (10)

Country Link
US (3) US20030068356A1 (enExample)
EP (2) EP1818029B1 (enExample)
JP (1) JP4617081B2 (enExample)
AT (1) ATE363261T1 (enExample)
AU (2) AU2002320385B2 (enExample)
CA (1) CA2451106C (enExample)
DE (1) DE60220408T2 (enExample)
DK (1) DK1406568T3 (enExample)
ES (2) ES2286263T3 (enExample)
WO (1) WO2003005944A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
EP1449525A1 (en) * 2003-02-20 2004-08-25 Cross Chem Llc chewing gum in the form of multi-layer tablets
KR100767271B1 (ko) * 2003-07-11 2007-10-17 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
UA81335C2 (uk) * 2003-07-11 2007-12-25 Ф.Хоффманн-Ля Рош Аг Оральна дозована форма саквінавіру мезилату
CN1819821B (zh) 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
KR101184138B1 (ko) 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
NZ548215A (en) * 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
KR20070030178A (ko) * 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US7615028B2 (en) * 2004-12-03 2009-11-10 Chf Solutions Inc. Extracorporeal blood treatment and system having reversible blood pumps
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
US20070287740A1 (en) 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
BRPI0609984A2 (pt) * 2005-05-25 2010-05-18 Transcept Pharmaceuticals Inc uso de zolpidem ou um sal do mesmo
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
US20110009692A1 (en) * 2007-12-26 2011-01-13 Yossi Gross Nitric oxide generation to treat female sexual dysfunction
US20090198271A1 (en) * 2008-01-31 2009-08-06 Rainbow Medical Ltd. Electrode based filter
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010118232A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Controlled-release clozapine compositions
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
US20110202108A1 (en) * 2010-02-18 2011-08-18 Rainbow Medical Ltd. Electrical menorrhagia treatment
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
HRP20161634T1 (hr) 2012-05-02 2017-01-13 Orexo Ab Novi pripravak alfentanila za liječenje akutne boli
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
BR112017013311B1 (pt) 2014-12-23 2022-05-31 Acelrx Pharmaceuticals, Inc Aparelho para a dispensação de formas de dosagem via oral e transmucosal
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004757A1 (en) * 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
FR2732217A1 (fr) * 1995-03-29 1996-10-04 Hesnard Xavier Forme d'administration solide a usage oral
WO2000035418A2 (en) * 1998-12-18 2000-06-22 Bayer Corporation Chewable drug delivery system
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6242002B1 (en) * 1998-03-31 2001-06-05 Arzneimittelwerk Dresden Gmbh Effervescent formulations
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4756710A (en) 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4764375A (en) 1985-09-11 1988-08-16 Kv Pharmaceutical Company Sachet drug delivery system
GB8820327D0 (en) * 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
DE3838431A1 (de) * 1988-11-12 1990-05-17 Bayer Ag Ibuprofen-brausezubereitungen
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
TW212139B (enExample) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
IT1270831B (it) 1993-09-17 1997-05-13 Romano Deghenghi Composizioni farmaceutiche orali effervescenti contenenti estrone
JP3021661B2 (ja) * 1994-03-07 2000-03-15 セラテック・インコーポレーテッド 薬剤含有接着複合体の経皮放出デバイス
DE69535127T2 (de) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
JP3170139B2 (ja) 1994-04-08 2001-05-28 エスエス製薬株式会社 発泡性錠剤
AU1958295A (en) * 1994-04-13 1995-11-10 Novartis Ag Temporally controlled drug delivery systems
NZ288185A (en) 1994-06-15 1998-02-26 Dumex Alpharma As Particulate pharmaceutical formulation containing coated cores comprising at least 80% of an inert carrier having a friability of <20%; the inert carrier can be calcium carbonate
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
CA2160423A1 (en) * 1994-11-02 1996-05-03 Hemant N. Joshi Salts of nefazodone having improved dissolution rates
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2236368C (en) * 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
JP4815053B2 (ja) 1998-08-13 2011-11-16 シーマ・ラブス、インコーポレイテッド 経口投与の固形投与形態物としてのマイクロエマルション
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6326384B1 (en) * 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
KR101184138B1 (ko) * 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
NZ548215A (en) * 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
US20070036853A1 (en) * 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004757A1 (en) * 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
FR2732217A1 (fr) * 1995-03-29 1996-10-04 Hesnard Xavier Forme d'administration solide a usage oral
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6242002B1 (en) * 1998-03-31 2001-06-05 Arzneimittelwerk Dresden Gmbh Effervescent formulations
WO2000035418A2 (en) * 1998-12-18 2000-06-22 Bayer Corporation Chewable drug delivery system
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution

Also Published As

Publication number Publication date
ATE363261T1 (de) 2007-06-15
US20050031677A1 (en) 2005-02-10
HK1106126A1 (en) 2008-03-07
EP1406568A4 (en) 2004-12-15
EP1818029B1 (en) 2016-09-07
EP1818029A3 (en) 2008-06-11
US20030232080A1 (en) 2003-12-18
DE60220408T2 (de) 2008-01-31
AU2008203464A1 (en) 2008-08-21
EP1406568A1 (en) 2004-04-14
DK1406568T3 (da) 2007-10-01
AU2008203464B2 (en) 2010-07-01
JP4617081B2 (ja) 2011-01-19
CA2451106A1 (en) 2003-01-23
EP1818029A2 (en) 2007-08-15
WO2003005944A1 (en) 2003-01-23
ES2604780T3 (es) 2017-03-09
EP1406568B1 (en) 2007-05-30
US20030068356A1 (en) 2003-04-10
JP2004534839A (ja) 2004-11-18
US7670617B2 (en) 2010-03-02
DE60220408D1 (de) 2007-07-12
CA2451106C (en) 2009-12-22
ES2286263T3 (es) 2007-12-01

Similar Documents

Publication Publication Date Title
CA2451106C (en) Sequential drug delivery systems
AU2002320385A1 (en) Sequential drug delivery systems
CA2335566C (en) Effervescent drug delivery system for oral administration
ES2301537T3 (es) Comprimidos y formulacion de guaifenesina de liberacion sostenida.
JP5730572B2 (ja) 濫用抵抗性製剤
Ubhe et al. A brief overview on tablet and it’s types
JPH10510559A (ja) シサプリドの即時放出性ｐＨ非依存性固形製剤
JP2006524650A (ja) 口腔内崩壊錠
JP2012500230A (ja) 胃内滞留薬物放出システム及びその製造方法と使用
CA2320193A1 (en) Controlled release preparation
KR20060028767A (ko) 다중층 구강분산성 정제
CN112315927A (zh) 一种帕利哌酮缓释口崩片及其制备方法
HK1106126B (en) Sequential drug delivery systems
KR102046395B1 (ko) 베포타스틴 또는 이의 약제학적으로 허용 가능한 염을 포함하는 서방성 제제
EP0803251A1 (en) Immediate release pH-independent solid dosage form of cisapride
JP2002504107A (ja) （＋）−または（−）−シサプリドの即時放出性ｐＨ非依存的固形投薬剤形
AU2005202472B2 (en) Effervescent drug delivery system for oral administration
KR20220085746A (ko) 염산 클로미프라민의 제어 방출을 위한 이중정 및 이의 제조방법
TW202037368A (zh) 治療精神疾病之控釋藥物組合物和方法
Borole FORMULATION, DEVELOPMENT AND EVALUATION OF FLOATING-PULSATILE DRUG DELIVERY SYSTEM OF NIFEDIPINE
JPWO1999040942A1 (ja) 放出制御製剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired